Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer

Breast Cancer Research and Treatment

Volumn 85, Issue 1, 2004, Pages 89-97

  Gallicchio, Lisa ^a   Lord, Gwyn ^b   Tkaczuk, Katherine ^a   Danton, Malcolm ^b   Lewis, Lynn M ^a   Lim, Chang K ^b   Flaws, Jodi A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

4 hydroxytamoxifen; Breast cancer; Metabolism; N desmethyltamoxifen; Side effects; Tamoxifen; Vaginal discharge; Visual problems

Indexed keywords

4 HYDROXYTAMOXIFEN; DRUG METABOLITE; ESTROGEN RECEPTOR; NORTAMOXIFEN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; AMNESIA; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT FLUSH; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MIGRAINE; MUSCLE WEAKNESS; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SIDE EFFECT; VAGINA DISCHARGE; VAGINAL DRYNESS; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HOT FLASHES; HUMANS; MENTAL DISORDERS; MIDDLE AGED; NAUSEA; NERVOUS SYSTEM DISEASES; QUESTIONNAIRES; TAMOXIFEN; VAGINAL DISEASES;

EID: 1842607090     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000021050.92539.b0     Document Type: Article

References (27)

1. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG: Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97: 855-866, 2001
2. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205, 1984
3. Early Breast Cancer Trialists' Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998
4. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, Meakin JW, Shelley W, Pritchard KI: An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44: 201-210, 1997
5. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16-21, 1981
6. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998
7. Mourits MJ, Bockermann I, de Vries EG, van der Zee AG, ten Hoor KA, van der Graaf WT, Sluiter WJ, Willemse PH: Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 86: 1546-1550, 2002
8. Fellowes D, Fallowfield LJ, Saunders CM, Houghton J: Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat 66: 73-81, 2001
9. Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, Francois E, Namer M, Ferrero JM, Milano G: Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 59: 401-410, 1996
10. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN: Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529, 1995
11. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21: 645-656, 1993
12. Crewe HK, Ellis SW, Lennard MS, Tucker GT: Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53: 171-178, 1997
13. Fabian C, Tilzer L, Sternson L: Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 2: 381-390, 1981
14. Jones RM, Yuan ZX, Lamb JH, Lim CK: On-line high-performance liquid chromatographic-electrospray ionization mass spectrometric method for the study of tamoxifen metabolism. J Chromatogr A 722: 249-255, 1996
15. Jones RM, Yuan ZX, Lim CK: Tamoxifen metabolism in rat liver microsomes: identification of a dimeric metabolite derived from free radical intermediates by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 13: 211-215, 1999
16. SAS Institute Inc.: SAS/STAT Guide for Personal Computers, Version 6.04. SAS Institute, Inc., Cary, NC, 1987
17. Baker VL, Jaffe RB: Clinical uses of antiestrogens. Obstet Gynecol Surv 51: 45-59, 1996
18. Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, Sandri MT, Barreca A, Costa A, Robertson C, Lien EA: Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17: 2633-2638, 1999
19. Kaiser-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep 62: 315-320, 1978
20. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Hargolese RG, Mathen MK, Bowman DM, Kaufman DI, Dimitrov NV, Singerman LJ, Bornstein R, Wolmark N, Kaufmann D: Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 125: 493-501, 1998
21. Paganini-Hill A, Clark LJ: Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60: 167-172, 2000
22. Flaxel CJ, Mulholland B, Haynes B, Gregor ZJ: Intraocular penetration of tamoxifen. Ophthalmology 107: 2006-2009, 2000
23. Imperia PS, Lazarus HM, Lass JH: Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 34: 209-230, 1989
24. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919-3924, 1993
25. Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintenig GM, Sepulveda FV, Gill DR, Hyde SC, Trezise AE, Higgins CF: Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest 94: 1690-1697, 1994
26. Buckley MM, Goa KL: Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 37: 451-490, 1989
27. Etienne MC, Milano G, Fischel JL, Frenay M, Francois E, Formento JL, Gioanni J, Namer M: Tamoxifen metabolism: pharmacokinetic and in vitro study. Br J Cancer 60: 30-35, 1989